Clinical assessment of momelotinib drug-drug interactions via CYP3A metabolism and transporters
Clin Transl Sci. 2024 Apr;17(4):e13799. doi: 10.1111/cts.13799.ABSTRACTMomelotinib-approved for treatment of myelofibrosis in adults with anemia-and its major active metabolite, M21, were assessed as drug-drug interaction (DDI) victims with a strong cytochrome P450 (CYP) 3A4 inhibitor (multiple-dose ritonavir), an organic anion transporting polypeptide (OATP) 1B1/1B3 inhibitor (single-dose rifampin), and a strong CYP3A4 inducer (multiple-dose rifampin). Momelotinib DDI perpetrator potential (multiple-dose) was evaluated with CYP3A4 and breast cancer resistance protein (BCRP) substrates (midazolam and rosuvastatin, respecti...
Source: Clinical Genitourinary Cancer - April 18, 2024 Category: Cancer & Oncology Authors: Yu Liu Ho Pete Gorycki Geraldine Ferron-Brady Paul Martin Georgios Vlasakakis Source Type: research
Incidence of chemotherapy-related cardiac dysfunction in cancer patients
CONCLUSION: Our meta-analysis unveiled a definitive overall incidence rate of chemotherapy-related cardiac dysfunction in cancer patients. In addition, it was found that the risk of developing this condition escalates within the initial 6 months postchemotherapy, subsequently tapering off to become statistically insignificant after a duration of 6 years.PMID:38634453 | DOI:10.1002/clc.24269 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 18, 2024 Category: Cancer & Oncology Authors: Hai-Wei Deng Rui Fan Yuan-Sheng Zhai Jie Li Zhi-Bin Huang Long-Yun Peng Source Type: research
The impact of advancing the standard of care in radiotherapy on operational treatment resources
CONCLUSION: The clinical implementation of hypofractionated treatment regimens has successfully reduced the radiotherapy workload and operational treatment hours required to treat patients. This analysis describes the impact of changes to the standard of care on institutional resources.PMID:38634814 | DOI:10.1002/acm2.14363 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 18, 2024 Category: Cancer & Oncology Authors: Michael Roumeliotis Kundan Thind Hali Morrison Ben Burke Kevin Martell Lukas van Dyke Lisa Barbera Sarah Quirk Source Type: research
Methodology for Using Real-World Data From Electronic Health Records to Assess Chemotherapy Administration in Women With Breast Cancer
CONCLUSION: We describe the challenges and approaches to operationalize complex, real-world data to identify intended chemotherapy regimens in large, observational studies. This methodology can improve efficiency of use of large-scale clinical data in real-world populations, helping answer critical questions to improve care delivery and patient outcomes.PMID:38635936 | DOI:10.1200/CCI.23.00209 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 18, 2024 Category: Cancer & Oncology Authors: Jenna Bhimani Kelli O'Connell Isaac J Ergas Marilyn Foley Grace B Gallagher Jennifer J Griggs Narre Heon Tatjana Kolevska Yuriy Kotsurovskyy Candyce H Kroenke Cecile A Laurent Raymond Liu Kanichi G Nakata Sonia Persaud Donna R Rivera Janise M Roh Sara Tab Source Type: research
Bench-to-bedside imaging in brain metastases: a road to precision oncology
This article offers insight into the molecular biology underlying brain metastasis, its pathogenesis, imaging protocols, and algorithms. It also discusses disease-specific molecular imaging features, focusing on common tumors that spread to the brain, such as lung, breast, colorectal cancer, melanoma, and renal cell carcinoma. Additionally, it covers various targeted treatment options, criteria for assessing treatment response, and the role of artificial intelligence in diagnosing, managing, and predicting prognosis for patients with brain metastases.PMID:38637186 | DOI:10.1016/j.crad.2024.02.015 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 18, 2024 Category: Cancer & Oncology Authors: S Shukla A Karbhari S Rastogi U Agarwal P Rai A Mahajan Source Type: research
Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119
J Pathol Clin Res. 2024 May;10(3):e12371. doi: 10.1002/2056-4538.12371.ABSTRACTThe efficacy of pembrolizumab monotherapy versus chemotherapy increased with increasing programmed death ligand 1 (PD-L1) expression, as quantified by combined positive score (CPS; PD-L1 expression on both tumour cells and immune cells) in patients with previously treated metastatic triple-negative breast cancer (mTNBC) in the phase 3 KEYNOTE-119 study. This exploratory analysis was conducted to determine whether the expression of PD-L1 on tumour cells contributes to the predictive value of PD-L1 CPS in mTNBC. PD-L1 expression in tumour samples ...
Source: Clinical Genitourinary Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Javier Cortes Eric P Winer Oleg Lipatov Seock-Ah Im Anthony Gon çalves Eva Mu ñoz-Couselo Keun Seok Lee Peter Schmid Kenji Tamura Laura Testa Isabell Witzel Shoichiro Ohtani Stephanie Hund Karina Kulangara Vassiliki Karantza Jaime A Mejia Junshui Ma Pet Source Type: research
Maintenance pembrolizumab therapy in patients with metastatic HER2-negative breast cancer with prior response to chemotherapy
CONCLUSIONS: Pembrolizumab monotherapy achieved durable treatment responses. Patients with a high baseline T-cell clonality had prolonged disease control with pembrolizumab.PMID:38629963 | DOI:10.1158/1078-0432.CCR-23-2947 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Toshiaki Iwase Evan N Cohen Hui Gao Angela Alexander Megumi Kai Vivian Chiv Xiaoping Wang Savitri Krishnamurthy Diane Liu Yu Shen Kumiko Kida Alexandre Reuben Rachel Layman David Ramirez Debu Tripathy Stacy L Moulder Clinton Yam Vicente Valero Bora Lim Ja Source Type: research
Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan
CONCLUSION: Genetic abnormalities with treatment options were found in 62.7% of advanced thyroid carcinomas. TP53 abnormality was an independent poor prognostic factor for overall survival in differentiated thyroid carcinoma. The time to treatment failure for lenvatinib was not different based on genetic profile.PMID:38630010 | DOI:10.1210/clinem/dgae271 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Soji Toda Yukihiko Hiroshima Hiroyuki Iwasaki Katsuhiko Masudo Source Type: research
Efficacy of pembrolizumab and biomarker analysis in patients with WGS-based intermediate to high tumor mutational load: results from the Drug Rediscovery Protocol
CONCLUSION: While in cohort A pembrolizumab lacked activity, cohort B and cohort C met the study's primary endpoint. Further research is warranted to refine selection of patients with tumors harboring lower TMLs and may benefit from a focus on innate immunity.PMID:38630551 | DOI:10.1158/1078-0432.CCR-24-0011 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Birgit S Geurts Laurien J Zeverijn Lindsay V M Leek Jade M van Berge Henegouwen Louisa R Hoes Hanneke van der Wijngaart Vincent van der Noort Joris van de Haar Annemiek van Ommen-Nijhof Marleen Kok Paul Roepman Anne M L Jansen Wendy W J de Leng Maja J A d Source Type: research
NTRK-rearranged spindle cell neoplasm: Initial observation of imaging appearance and clinicopathologic correlation
CONCLUSION: NTRK-rearranged neoplasms may occur as enhancing masses with linear hypointense signal foci on MRI and FDG avid metastases on PET. Pulmonary metastases were frequent in our study. Initial treatment response is observed in most patients.PMID:38631176 | DOI:10.1016/j.clinimag.2024.110134 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Matthew Spano Cecilia Davis-Hayes Meera Hameed Ryma Benayed Sinchun Hwang Source Type: research
Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119
J Pathol Clin Res. 2024 May;10(3):e12371. doi: 10.1002/2056-4538.12371.ABSTRACTThe efficacy of pembrolizumab monotherapy versus chemotherapy increased with increasing programmed death ligand 1 (PD-L1) expression, as quantified by combined positive score (CPS; PD-L1 expression on both tumour cells and immune cells) in patients with previously treated metastatic triple-negative breast cancer (mTNBC) in the phase 3 KEYNOTE-119 study. This exploratory analysis was conducted to determine whether the expression of PD-L1 on tumour cells contributes to the predictive value of PD-L1 CPS in mTNBC. PD-L1 expression in tumour samples ...
Source: Clinical Genitourinary Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Javier Cortes Eric P Winer Oleg Lipatov Seock-Ah Im Anthony Gon çalves Eva Mu ñoz-Couselo Keun Seok Lee Peter Schmid Kenji Tamura Laura Testa Isabell Witzel Shoichiro Ohtani Stephanie Hund Karina Kulangara Vassiliki Karantza Jaime A Mejia Junshui Ma Pet Source Type: research
Maintenance pembrolizumab therapy in patients with metastatic HER2-negative breast cancer with prior response to chemotherapy
CONCLUSIONS: Pembrolizumab monotherapy achieved durable treatment responses. Patients with a high baseline T-cell clonality had prolonged disease control with pembrolizumab.PMID:38629963 | DOI:10.1158/1078-0432.CCR-23-2947 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Toshiaki Iwase Evan N Cohen Hui Gao Angela Alexander Megumi Kai Vivian Chiv Xiaoping Wang Savitri Krishnamurthy Diane Liu Yu Shen Kumiko Kida Alexandre Reuben Rachel Layman David Ramirez Debu Tripathy Stacy L Moulder Clinton Yam Vicente Valero Bora Lim Ja Source Type: research
Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan
CONCLUSION: Genetic abnormalities with treatment options were found in 62.7% of advanced thyroid carcinomas. TP53 abnormality was an independent poor prognostic factor for overall survival in differentiated thyroid carcinoma. The time to treatment failure for lenvatinib was not different based on genetic profile.PMID:38630010 | DOI:10.1210/clinem/dgae271 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Soji Toda Yukihiko Hiroshima Hiroyuki Iwasaki Katsuhiko Masudo Source Type: research
Efficacy of pembrolizumab and biomarker analysis in patients with WGS-based intermediate to high tumor mutational load: results from the Drug Rediscovery Protocol
CONCLUSION: While in cohort A pembrolizumab lacked activity, cohort B and cohort C met the study's primary endpoint. Further research is warranted to refine selection of patients with tumors harboring lower TMLs and may benefit from a focus on innate immunity.PMID:38630551 | DOI:10.1158/1078-0432.CCR-24-0011 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Birgit S Geurts Laurien J Zeverijn Lindsay V M Leek Jade M van Berge Henegouwen Louisa R Hoes Hanneke van der Wijngaart Vincent van der Noort Joris van de Haar Annemiek van Ommen-Nijhof Marleen Kok Paul Roepman Anne M L Jansen Wendy W J de Leng Maja J A d Source Type: research
NTRK-rearranged spindle cell neoplasm: Initial observation of imaging appearance and clinicopathologic correlation
CONCLUSION: NTRK-rearranged neoplasms may occur as enhancing masses with linear hypointense signal foci on MRI and FDG avid metastases on PET. Pulmonary metastases were frequent in our study. Initial treatment response is observed in most patients.PMID:38631176 | DOI:10.1016/j.clinimag.2024.110134 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Matthew Spano Cecilia Davis-Hayes Meera Hameed Ryma Benayed Sinchun Hwang Source Type: research
